Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIL101 in Locally Advanced or Metastatic Solid Tumors
NCT06626256Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
01
Overview
Phase 1, open-label, single-arm trial of STIL-101 in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), renal cell carcinoma (RCC) and 2 more, sponsored by City of Hope. Primary endpoints: Infusion limiting toxicities at 28 days and Treatment-related adverse events at 2 years. Planned start Dec 2025; status: withdrawn.
02
Drugs
STIL-101
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)renal cell carcinoma (RCC)Cervical Cancer (CC)melanoma
Beyond the preview
Go deeper on NCT06626256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626256.